<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016196</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/12/0551</org_study_id>
    <nct_id>NCT02016196</nct_id>
  </id_info>
  <brief_title>Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS</brief_title>
  <acronym>PRPET</acronym>
  <official_title>Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TIPS has been used for 20 years, as a means of reducing portal pressure in patients with&#xD;
      cirrhosis and portal hypertension related complications. TIPS proved more effective than&#xD;
      alternative treatments in controlling or preventing variceal bleeding and refractory ascites.&#xD;
      The main drawback of the TIPS procedure is progressive overt hepatic encephalopathy (OHE).&#xD;
      Three risk factors for post-TIPS OHE have been identified: age over 65 years, history of&#xD;
      previous episodes of OHE, and Child-Pugh score equal to or over 10. However, the incidence of&#xD;
      post-TIPS OHE in patients fulfilling these criteria remains close to 35 %.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TIPS has been used for 20 years, as a means of reducing portal pressure in patients with&#xD;
      cirrhosis and portal hypertension related complications. TIPS proved more effective than&#xD;
      alternative treatments in controlling or preventing variceal bleeding and refractory ascites.&#xD;
      The main drawback of the TIPS procedure is progressive overt hepatic encephalopathy (OHE).&#xD;
      Three risk factors for post-TIPS OHE have been identified: age over 65 years, history of&#xD;
      previous episodes of OHE, and Child-Pugh score equal to or over 10. However, the incidence of&#xD;
      post-TIPS OHE in patients fulfilling these criteria remains close to 35 %. Furthermore, the&#xD;
      pathogenesis of HE in general but also in patients treated by TIPS is still not well&#xD;
      understood. Therefore, there is a real challenge in discovering new molecular mechanisms&#xD;
      involved in pathogenesis of OHE as well as new treatment to better prevent the risk of OHE in&#xD;
      patients treated by TIPS. Observational and experimental studies suggest a microbiota's role&#xD;
      in the mechanism of OHE and recently a non absorbable antibiotic has proven to reduce the&#xD;
      risk of recurrence of OHE. However, the effect of this drug for the prevention of a first&#xD;
      episode of OHE in patients treated by TIPS is not known. In addition, the mechanisms of the&#xD;
      beneficial effect of rifaximin remain poorly understood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First episode of overt encephalopathy in patients treated by TIPS</measure>
    <time_frame>6 months</time_frame>
    <description>First episode of overt encephalopathy in patients treated by TIPS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of hospitalisation days</measure>
    <time_frame>6 months</time_frame>
    <description>Number and days of hospitalisations for encephalopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of kidney insufficiency</measure>
    <time_frame>6 months</time_frame>
    <description>number of digestive bleeding follow up to portal hypertension, number of ascit punctions, frequency kidney insufficiency and hepatocellular carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplants, deaths</measure>
    <time_frame>6 months</time_frame>
    <description>- number of transplants and deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intestinal microbiota</measure>
    <time_frame>6 months</time_frame>
    <description>Composition of intestinal microbiota in 30 patients (only UHToulouse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 caps placebo morning and night, 15 days before and 6 months after TIPS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS&#xD;
--------------------------------------------------------------------------------</description>
    <arm_group_label>rifaximin</arm_group_label>
    <other_name>NORMIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cirrhosis with TIPS for ascit treatment or hydrothorax&#xD;
&#xD;
          -  prevention digestive bleeding follow up portal hypertension -&#xD;
&#xD;
          -  signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hepatocellular carcinoma out of Milan criteria or palliative phase cancer&#xD;
&#xD;
          -  Child Pugh score &gt; 12&#xD;
&#xD;
          -  TIPS indicated for other indication than bellow&#xD;
&#xD;
          -  encephalopathy signs : asterixis or confusion&#xD;
&#xD;
          -  Hypersensibility to rifaximin, or derivated of rifamycin&#xD;
&#xD;
          -  Patients treated by same class antibacterial&#xD;
&#xD;
          -  pregnant woman&#xD;
&#xD;
          -  Patient with hepatic transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Bureau, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Beaujon Clichy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHToulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIPS</keyword>
  <keyword>portal pressure</keyword>
  <keyword>rifaximin</keyword>
  <keyword>overt hepatic encephalopathy</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

